Oct 17 (Reuters) - ProMIS Neurosciences Inc
* ProMIS Neurosciences lead product candidate, PMN310, shows desired target binding profile in direct comparison to other amyloid beta-directed antibodies for alzheimer’s disease Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)
